Three Banks See Big Insider Stock Buys -- Barrons.com
Analysts' Opinions Are Mixed on These Healthcare Stocks: Align Tech (ALGN) and Gilead Sciences (GILD)
Hold Rating on Gilead Sciences Amidst Q2 Revenue Shortfall and Competitive Pressures
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
Analysts' Opinions Are Mixed on These Healthcare Stocks: Healthequity (HQY), Community Health (CYH) and Gilead Sciences (GILD)
Barclays Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $76
Buy Rating Affirmed: Sangamo's Hemophilia A Gene Therapy Poised for Success With Pfizer Partnership
Deutsche Bank Adjusts U.S. Bancorp Price Target to $51 From $49
Gilead Sciences (GILD) Receives a Buy From TD Cowen
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
Analysts' Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD)
Gilead Sciences: A Balanced Outlook With Steady HIV Performance and Oncology Challenges Justifying a Hold Rating
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Jasper Therapeutics (JSPR)
Gilead Sciences Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $70 From $75
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
Intl Flavors & Fragrances Price Target Raised to $115.00/Share From $95.00 by Stifel
Intl Flavors & Fragrances Analyst Ratings
Jefferies Sticks to Their Buy Rating for Gilead Sciences (GILD)
Wolfe Research Adjusts Price Target on International Flavors & Fragrances to $77 From $70